HT
MLTX icon

HAP Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

HAP Trading’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$223K Buy
+31,073
New +$1.62M 0.02% 389

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HAP Trading's MLTX Position: Q3 2025 in Review

HAP Trading opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2025: 31,073 shares worth $223K. The stake represents 0.02% of the portfolio and ranks #389 among its holdings.

134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • HAP Trading held 31,073 shares of MoonLake Immunotherapeutics worth $223K as of Q3 2025.
  • MoonLake Immunotherapeutics was a new HAP Trading position in Q3 2025.
  • MoonLake Immunotherapeutics made up 0.02% of HAP Trading's portfolio in Q3 2025, its #389 holding.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.